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Background: Respiratory syncytial virus (RSV) is the major respiratory pathogen of infants and young children.
During each seasonal epidemic, multiple strains of both subgroup A and B viruses circulate in the community. Like
other RNA viruses, RSV genome replication is prone to errors that results in a heterogeneous population of viral
strains some of which may possess differences in virulence. We sought to determine whether clinical isolates of RSV
differ in their capacity to induce inflammatory cytokines IL-6 and CCL5 (previously known as RANTES [regulated
upon activation, normal T-cell expressed and secreted protein]), which are known to be induced in vitro and in vivo
in response to RSV, during infection of A549 cells.
Results: Screening of subgroup A and B isolates revealed heterogeneity among strains to induce IL-6 and CCL5.
We chose two subgroup B strains, New Haven (NH)1067 and NH1125, for further analysis because of their marked
differences in cytokine inducing properties and because subgroup B strains, in general, are less genetically
heterogeneous as compared to subgroup A strains. At 12 and 24 hours post infection RSV strains, NH1067 and
NH1125 differed in their capacity to induce IL-6 by an order of magnitude or more. The concentrations of IL-6 and
CCL5 were dependent on the dose of infectious virus and the concentration of these cytokines induced by NH1125
was greater than that of those induced by NH1067 when the multiplicity of infection of NH1067 used was as much
as 10-fold higher than that of NH1125. The induction of IL-6 was dependent on viable virus as infection with UV-
inactivated virus did not induce IL-6. The difference in IL-6 induction most likely could not be explained by
differences in viral replication kinetics. The intracellular level of RSV RNA, as determined by quantitative RT-PCR, was
indistinguishable between the 2 strains though the titer of progeny virus produced by NH1125 was greater than
that produced by NH1067 at 16, 24 and 36 hours but essentially equal at 48 and 72 hours. Full genome sequencing
of the 2 strains revealed 193 polymorphisms and 4 insertions in NH1067when compared to NH1125 (2 single base
insertions in non-coding regions and 2 duplications of 3 and 60 bases in the RSV G gene). Of the polymorphisms,
147 occurred in coding regions and only 30 resulted in amino acid changes in 7 of the RSV genes.
(Continued on next page)* Correspondence: Jeffrey.Kahn@UTSouthwestern.edu
†Equal contributors
1Department of Pediatrics, University of Texas Southwestern Medical Center,
Dallas, TX, USA
2Department of Microbiology, University of Texas Southwestern Medical
Center, Dallas, TX, USA
Full list of author information is available at the end of the article
© 2012 Levitz et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Levitz et al. Virology Journal 2012, 9:190 Page 2 of 9
http://www.virologyj.com/content/9/1/190(Continued from previous page)
Conclusions: These data suggest that RSV strains may not be homogeneous with regard to pathogenesis or
virulence. Identification of the genetic polymorphisms associated with variations in cytokine induction may lead to
insights into RSV disease and to the development of effective antiviral agents and vaccines.
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Respiratory syncytial virus (RSV) is a major respiratory
pathogen of infants and young children as well as the
elderly and immunocompromised populations [1]. Clin-
ical isolates can be categorized into 1 of 2 major sub-
groups of RSV, A or B, by immunological or genetic
methods [2,3]. Within each subgroup, there are several
distinct genotypes, a variety of which co-circulate during
yearly epidemics [3-5].
The inflammatory response to RSV infection plays a
major role in the disease pathogenesis and this inflam-
mation may result in signs of restrictive and obstructive
lung disease long after RSV can be detected in respira-
tory secretions. RSV elicits the production of a variety of
cytokines and chemokines during and after infection
[6,7]. Both in vivo and in vitro data suggest that IL-6, a
pro-inflammatory cytokine, is a key component of the
response of the host to RSV infection. Microarray ana-
lysis of RSV-infected human alveolar type II epithelial
(A549) cells reveals that IL-6 mRNA was induced ~20-
fold 30 minutes after infection [8]. IL-6 is present in the
respiratory secretions of RSV-infected individuals and
serum levels of IL-6 are increased during RSV infection
















Figure 1 Screening of clinical isolates of RSV for induction of IL-6. A5
concentrations in cell culture supernatants at 24 hours post infection were
and subgroup B isolates are designated by the bars below the graph. Subg
experiments, are boxed.production is poorly understood. The chemokine CCL5
(previously known as RANTES [regulated upon activa-
tion, normal T-cell expressed and secreted protein]) is
induced in humans and animal models of RSV and evi-
dence suggests that this molecule plays an important
role in pathogenesis [6,11]. Therefore, exploration of the
induction of IL-6 and CCL5 by clinical isolates of RSV
may be insightful.
Several groups, including our own, have demonstrated
a potential association between viral genotype and sever-
ity of illness, suggesting that clinical isolates of RSV may
differ in virulence [9,12-15]. However, the study of
strain-specific factors in vivo is complicated by a variety
of host factors influencing the severity of infection. In
order to eliminate these factors, we chose to study strain
differences in a cell culture model system. As such, we
screened and plaque purified clinical isolates of RSV and
assessed their ability to induce cytokines in human al-
veolar type II epithelial (A549) cells. The results demon-
strate that clinical isolates differ dramatically in their
ability to induce certain cytokines in cell culture. These
findings suggest that the genetic variability of clinical
isolates of RSV may contribute to the severity of infec-
tion caused by the virus.BGA4
49 cells were infected with multiplicity of infection (moi) 1 and IL-6
measured by ELISA. Subgroup A isolates (clades GA2, GA3 and GA4)
roup B isolates NH1067 and NH1125, chosen for subsequent
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Screening of clinical isolates of RSV for their ability to
induce IL-6
Since 1998, we have propagated clinical strains of RSV
in cell culture and have performed phylogenetic analysis
of >200 of these isolates (data not shown). From this col-
lection of clinical isolates, we screened both subgroup A
and B isolates for their ability to induce the secretion of
IL-6 during infection of the pulmonary epithelial cell
line A549. We chose genetically diverse strains of sub-
group A (representing at least 3 distinct clades [12]) and
B isolates (based on previous phylogenetic analysis (data
not shown). The strains screened were not homogenous
in their cytokine induction properties (Figure 1). To fur-
ther explore this phenomenon, we chose 2 subgroup B
strains, New Haven (NH)1067 and NH1125 for further
investigation. These strains were chosen for 2 reasons: 1)
there were marked differences observed in the levels of
IL-6 induced between these strains (Figure 1, boxed) and;
2) subgroup B isolates are less genetically heterogeneous
as compared to subgroup A isolates. Our hypothesis was
that there would be fewer polymorphisms between pairs
of isolates of subgroup B as compared to subgroup A. If
so, study of subgroup B isolates would be preferable in
eventually identifying the viral genetic markers respon-
sible for cytokine induction. Both strains were isolated
from respiratory specimens collected in 2002. At 12
and 24 hours post-infection, the level of IL-6 induced
by NH1125 was at least an order of magnitude
























Figure 2 Induction of IL-6 by clinical isolates NH1067 and
NH1125. A549 cells were infected with multiplicity of infection
(moi) 1 and IL-6 concentrations in cell culture supernatants were
measured by ELISA. Ultraviolet light (UV) inactivated virus was used
as a control. Standard error bars are displayed.mechanism of this induction was explored. UV-
inactivated virus (both strains) failed to induce IL-6
(Figure 2) suggesting that viable virus, or at least
virus with transcriptional and genome replication ac-
tivity was required for induction of IL-6. These find-
ings also suggest that virus binding to the target cell,
which presumably still occurs with UV-inactivated
virus, was not sufficient for IL-6 induction.
Dynamics of replication of clinical isolates NH1067 and
NH1125
One potential explanation for the observed differences
in cytokine induction by NH1067 and NH1125 was that
the replication kinetics of the 2 viruses differed. To ad-
dress this possibility, viral replication kinetics were
assayed by 2 means: quantitative real time PCR and
traditional viral growth assays. Quantitative RT-PCR,
using primers specific for the negative sense genome
strand, revealed that the kinetics of genome replication
of NH1125 and NH1067 were identical (Figure 3). As
shown in Figure 4, production of infectious virus from
NH1067- or NH1125-infected cells at 48 and 72 hours
post-infection are identical though at earlier times, there
is less infectious virus detected in NH1067-infected
cells.
Induction of cytokines is dose-dependent
To further explore the differences in cytokine induction
by strains NH1067 and NH1125, infectious dose–re-
sponse experiments were performed. A549 cells were
infected with a multiplicity of infection (moi) of 0.013,
0.04 or 0.13 and supernatant levels of IL-6 and CCL5
were determined at 24 hours post-infection. As shown
in Figure 5 (a and b), induction of IL-6 and CCL5 by


























Figure 3 Viral replication kinetics of NH1067 and NH1125.
Intracellular viral genomic RNA levels were determined by real time
reverse transcriptase PCR. RNA quantity is displayed as pfu



















Figure 4 Plaque assay replication curves of NH1067 and
NH1125. A549 cells were infected with a moi of 0.2. At specific
times after infection, cells were harvested and viral titer was
determined by plaque assay.
Levitz et al. Virology Journal 2012, 9:190 Page 4 of 9
http://www.virologyj.com/content/9/1/190There also appeared to be a dose-dependent induction
of CCL5 in cells infected with NH1067. However,








































Figure 5 Dose response of induction of IL-6 and CCL5 in A549
cells during infection with NH1067 and NH1125. A549 cells were
infected with a moi of 0.013, 0.04 or 0.13 with either NH1067 or
NH1125. At 24 hours post infection, supernatant concentrations of
IL-6 (a)and CCL5 (b) were measured. Standard error bars are
displayed.cytokines. Of note, the levels of IL-6 and CCL5 induced
by NH1067 at a moi of 0.13 was essentially equivalent to
the levels of IL-6 and CCL5 induced by NH1125 at a
moi of 0.013, a ten-fold difference in infectious dose.
Genome sequence comparisons of NH1067 and NH1125
The genome of NH1067 contained 15,283 nucleotides
[GenBank: accession JQ582844] and the genome of
NH1125 contained 15,216 nucleotides [GenBank: acces-
sion JQ582843]. Overall, there were 194 polymorphisms
between the 2 viruses (Table 1). Nucleotide differences
were observed in every open reading frame (ORF)
though the majority (117/147) of the polymorphisms in
the coding sequences were synonymous. The exception
was the RSV G gene. Of the 23 polymorphisms detected
in the RSV G gene of NH1067 and NH1125, 13 resulted
in mis-sense mutations while 10 were silent. This is not
surprising as the RSV G gene is known to be the most
variable of all genes in the RSV genome [16,17]. The
RSV G gene of NH1067 contained 2 duplications, 3 and
60 nucleotides in length, which were not present in
NH1125. Viruses containing the 60 base duplication
were first identified in Buenos Aires in 1999 [18]. Subse-
quently, RSV subgroup B viruses with this 60 base inser-
tion have been identified worldwide [19].
Association of genotype and cytokine induction
phenotype
To determine whether other subgroup B isolates had
cytokine-inducing phenotypes similar to NH1067 or
NH1125, 8 additional viruses were assayed for their abil-
ity to induce IL-6 and CCL5. These additional viruses
were chosen because they were NH1067-like, NH1125-
like or distantly related to NH1067 and NH1125 based
on their G gene sequences some of which contained the
60-base duplication. As shown in Figure 6, the induction
profiles correlated, for the most part, with genotype.
NH1001 and NH1125 had similar cytokine induction
profiles and were closely related genetically. Likewise,
NH1067, Texas (TX)11-56 and NH1182, closely related
viruses, were poor cytokine inducers (low inducers).
However, NH1161, a relative outlier, had an IL-6 induc-
tion phenotype that was similar to NH1001. Of note, the
low induction phenotype does not seem to correlate
with the G gene duplication detected in NH1067.
Viruses containing the 60 base duplication (NH1067,
NH1182, TX11-56; designated with the * in Figure 5)
and viruses lacking this duplication (NH923, NH1144,
NH1262, NH1276) all had a low induction phenotype.
Polymorphisms in the F gene in NH1067 and NH1125
resulted in 4 amino acid differences at positions 67, 292,
490 and 529. It is unlikely that any of these 4 mutations
were the basis for the observed phenotype. Sequencing
of the F gene of the viruses represented in Figure 5 did
Table 1 Sequence comparisons of clinical isolates NH1067, NH1125
Genomic segmenta Length in basesb Nucleotide differences Non-sensec Mis-sensec Silentc
3’end-NS1 98 1
NS1 gene 420 1 1
NS1-NS2 107 0
NS2 gene 375 4 1 3
NS2-N 136 (137) 6
N gene 1176 16 1 15
N-P 32 0
P gene 726 5 1 4
P-M 186 (188) 11
M gene 771 10 10
M-SH 268 10
SH gene 198 4 4
SH-G 189 4
G gene 888 (951) 23 13 10
G-F 88 0
F gene 1725 20 4 16
F-M2-1 225 (226) 8
M2-1 gene 588 4 2 2
M2-1-M2-2d 35 0
M2-2 gene 273 4 4
M2-2-L 65 2
L gene 6501 59 8 51
L-5’end 216 2
Total 15216 (15283) 194 0 30 120
aGene coding sequences (“gene”) or intergenic (inter-ORF) segment listed unless otherwise noted (3’ and 5’ end).
bNH1067 length in () when it differs from NH1125. NH1067 G gene contains a 3 base and 60 base insertion.
cNon-sense, mis-sense and silent nucleotide differences between the 2 strains are listed for coding sequences only.
dM2-1 and M2-2 overlap by 35 nucleotides.
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dues at these positions in the F protein and cytokine in-
duction phenotype (data not shown).
Discussion
RSV elicits the production of a wide variety of cytokines
and chemokines during and after infection [6,7,20-23].
There is now mounting evidence that the type of im-
mune response to RSV, specifically the spectrum of host
cytokine and chemokine production, ultimately affects
disease pathogenesis and chronicity [6]. Cytokine ex-
pression likely affects the balance between viral clear-
ance and progression of disease. Therefore, there is a
critical need to identify viral factors that regulate cyto-
kine expression during RSV infection [6].
The vast majority of studies into RSV pathogenesis
have used laboratory strains or recombinant virus
derived from these laboratory strains. These laboratory
strains were isolated decades ago and the passage histor-
ies of these strains are not known or are poorlydocumented. Several studies suggest that sole investiga-
tion of laboratory strains may not be ideal to define and
characterize RSV pathogenesis. For example, Line 19, a
potential vaccine strain derived from a subgroup A iso-
late possesses biological features that differ from the
reference strain A2 (isolated in Australia in 1961) [24].
These phenotypic differences have been mapped to poly-
morphisms in the RSV F gene [25]. Reference strain A2
differs from several clinical isolates in its ability to repli-
cate on primary human bronchial epithelial cells and to
induce interferon-inducible protein 10 and CCL5 sug-
gesting that A2 alone may not be the ideal strain to
study RSV pathogenesis [26]. Recently, Stokes et al.
demonstrated that several clinical isolates differ in their
capacity to induce airway mucous production and viru-
lence in mice [27]. Therefore, the study of clinical
isolates will likely yield important insights into the fun-
damental aspects of pathogenesis.
At least 2 RSV proteins have been implicated in the




























































NH1001 NH1125 NH923 NH1067*TX11-56*NH1182* NH1144 NH1262 NH1276 NH1161
Figure 6 Phenotypic and genotypic association of induction of IL-6 and CCL5 by clinical isolates of RSV. A549 cells were infected with
clinical isolates at a moi of 0.13. Cytokine levels (IL-6 and CCL5) in cell culture supernatants were measured at 16 hours after infection. Groupings
of clinical isolates were based on phylogenetic analysis of the RSV G gene as demonstrated by the phylogram beneath the graph. Viruses
containing the RSV G gene 60 base duplication are designated with the *.
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complex by promoting nuclear translocation of NF-ĸB
[28]. IL-6, along with other cytokines, such as IL-1β and
IL-8, play an important role in neutrophil and macro-
phage chemotaxis. The cellular inflammatory response
during severe RSV infection is characterized by a pre-
ponderance of neutrophils and macrophages, suggesting
that the expression of IL-6 at the site of infection is an
essential feature in disease progression [29]. Differences
in IL-6 induction may explain, in part, differences in se-
verity of illness seen with RSV infection. Indeed, clinical
studies of both infants and adults have demonstrated
that single nucleotide polymorphisms in the IL-6 pro-
moter (position −174) were associated with a greater se-
verity of illness suggesting a pivotal role of IL-6 in RSV
pathogenesis [30,31]. Our data suggests that variability
in the induction of IL-6 may, at least, partially explain
differences in the observed severity of human RSV dis-
ease associated with infection due to specific RSV geno-
types [9,12-15]. The RSV F protein of NH1067 and
NH1125 differs at only 4 amino acid residues (positions
67, 292, 490 and 529). It did not appear that these amino
acid changes can account for the differences in induction
of IL-6 observed because the specific amino acid resi-
dues at these positions did not correlate to induction
phenotype when other strains were examined.Several lines of evidence indicate that the RSV G
glycoprotein also plays a role in pathogenesis and can in-
duce IL-6 among other cytokines [32-37]. Monocyte
stimulation experiments using recombinant viruses with
altered or absent G gene and synthetic peptides, corre-
sponding to regions of the RSV G protein, revealed that
portions of the highly conserved cysteine-rich region,
specifically amino acids 164–176, inhibit the innate im-
mune response [37]. The CX3C motif (amino acid 182–
186) of the RSV G glycoprotein mimics the CX3C
chemokine fractalkine, competes for the chemokine-
specific receptor and interferes with fractalkine-mediated
leukocyte chemotaxis [32]. RSV deficient in the soluble
form of G (generated by initiation at the second AUG cor-
responding to amino acid 48) induced a pro-inflammatory
response in A549 cells [38]. Amino acids 164–176 and
182–186 were identical in NH1067 and NH1125. Both
strains contained a methionine at position 48. Therefore,
these regions of the RSV G gene, although likely import-
ant for cytokine induction pathways, cannot account for
the differences observed in IL-6 induction between
NH1067 and NH1125.
Our data suggest that the differences in the RSV F
protein between NH1067 and NH1125 are unlikely to
account for the differences in cytokine induction pheno-
type strongly suggesting that other viral factors, perhaps
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the differences in cytokine induction observed in the
clinical isolates. These factors may not necessarily be
viral proteins. A single nucleotide substitution in the
transcriptional start signal of the M2 gene, within a non-
coding region of the RSV genome [39] is the major
determinant of the temperature-sensitive, attenuated
phenotype of a potential vaccine candidate. However,
the consensus transcriptional start and stop signals for
each gene were identical between NH1067 and NH1125.
It appears as though viral transcriptional and/or replica-
tion activity rather than binding of virion-associated gly-
coproteins to cellular receptors is required as UV-
inactivated virus failed to induce IL-6, an observation
that has been reported elsewhere [40,41].
RSV causes a wide-spectrum of disease and this may
be due, in part, to the differences in biological properties
of the infecting virus. This phenomenon has been
observed with other viruses. For example, mutations in
the HCV NS5A gene are associated with a sustained
virological response to interferon therapy [42]. A neuro-
tropic variant of HIV, containing a mutation in the enve-
lope gene, has been identified, which is present at a high
frequency in brain tissue in AIDS patients with dementia
[43]. Mutations in several genes may account for the
increased virulence of the 1918 influenza pandemic
strain [44]. Identification of the viral gene(s) involved in
the induction of key cytokines, chemokines and inflam-
matory mediators would potentially lead to targeted
antiviral therapies and would be a significant advance in
the study of RSV pathogenesis.
Conclusion
This work demonstrates that clinical isolates of RSV are
not homogeneous in their ability to induce specific cyto-
kines. Screening of a relatively small number of clinical
isolates resulted in the identification of strains, NH1067
and NH1125, with markedly different cytokine-inducing
phenotypes. This work demonstrates the utility of
investigating clinical isolates, whose naturally-occurring
mutations result in distinct phenotypes. These data sug-
gest that further investigation, particularly with the use
of primary human cells (airway epithelial cells or
PBMCs), of these and other clinical isolates of RSV may
yield insights into pathogenesis and virulence.
Methods
Viruses and cells
HEp-2 (CCL-23) and A549 (CCL-185) cells were
obtained from the American Type Culture Collection
(Manassas, VA) and cultivated in EMEM with 10 % fetal
bovine serum. HEp-2 cells were used in the initial
propagation and titration of the clinical strains; A549
cells were used in the cytokine experiments describedbelow. Clinical isolates were obtained from RSV-infected
individuals as described previously from New Haven,
Connecticut [12] and Dallas, Texas. Viruses used in this
study were propagated from specimens submitted to the
clinical (diagnostic) laboratory (in New Haven, CT and
Dallas, TX). All specimens from which viruses were
obtained were submitted as part of routine care. Only
left over material was used for viral propagation. Collec-
tion of specimens from the Clinical Virology Laboratory
at Yale-New Haven Hospital was approved by the Yale
University Human Investigations Committee. The single
isolate from Dallas, Texas was propagated from a de-
identified clinical specimen obtained from the Clinical
Microbiology Laboratory at Children’s Medical Center,
Dallas. Collection and use of clinical isolates followed all
institutional requirements and guidelines and was con-
sistent with policies and regulations for the use of pa-
tient derived materials.
Isolates were plaque purified 3 times on HEp-2 cells.
Working stocks were prepared using 30%-60% (w/v)
non-continuous sucrose density centrifugation (SW-28,
28,000 rpm, 4°C for 90 minutes). The virus containing
band at the 30%-60% interface was collected, distributed
into aliquots, and stored at −80°C. Viral titers were
determined using a plaque assay [45]. Plaques were
detected with an immunohistochemical staining tech-
nique using either goat anti-RSV HRP-conjugated anti-
body (Fitzgerald Industries International, Acton, MA) or
a primary anti-RSV antibody (palivizumab, MedImmune,
Gaithersberg, MD) and secondary HRP conjugated anti-
human antibody (Jackson ImmunoResearch Laborator-
ies, Inc., West grove, PA). Viruses were inactivated by
subjecting viral inoculums to 2 doses of 5,000 joules of
ultraviolet (UV) light. UV-inactivation was confirmed by
cell culture.
Cytokine assays
Monolayers of A549 cells were infected with sucrose-
purified clinical isolates of RSV at the moi designated in
the text. After 90 minutes of infection, the inoculum was
removed, the cells were washed with serum-free media
and fresh media (F-12 Kaighn’s modification) containing
5% FBS was added to the infected monolayers. For cyto-
kine analysis, supernatants were collected, clarified by
centrifugation, snap frozen in liquid nitrogen and stored
at −80°C until the specific assay was performed. For the
initial screening of clinical isolates, the concentration of
IL-6 was determined by ELISA using the DuoSet Human
IL-6 ELISA kit (R&D Systems, Minneapolis, MN)
according to the manufacturer’s specifications. Standard
curves with known concentrations of IL-6 were
performed for each assay. All samples were analyzed on
the same ELISA plate to minimize technical bias and
there were at least 3 biological replicates for each
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tions of IL-6 and CCL5, BioPlex assays were performed
using Bio-Plex Pro™ with conjugated magnetic beads
according to the manufacturer’s instructions. Cytokine data
were analyzed using Bio-Plex Manager™ version 4.1.1
software.Real time PCR
Total RNA was extracted from A549 cell monolayers using
the RNeasy Mini kit and QIAshredder columns (QIAGEN,
Valencia, CA) according to the manufacturer’s recommen-
dations. RNA extracts were treated with RNase-free DNase
I (Roche), then reverse transcribed with Moloney murine
leukemia virus reverse transcriptase (New England BioLabs)
with a primer specific for the genomic (negative-sense)
copy of the RSV N gene, 5'-ATGGCTCTTAGCAAAGTC-
3'. PCR amplification of cDNA was performed in a reaction
mixture containing 5 μL cDNA template, forward (5'-CT
GTCATCCAGCAAATACACTATTCA-3') and reverse (5'-
GCACATCATAATTGGGAGTGTCA-3') primers at a con-
centration of 400 nM each, and 12.5 μL iQ SYBR Green
Supermix (Bio-Rad) in a total volume of 25 μL. Reaction
conditions were as follows: 95°C for 10 minutes, followed by
40 cycles of 95°C for 15 seconds and 60°C for 1 minute. For
cDNA standards, RNA was extracted from plaque-titered
stocks of the laboratory reference B strain 8/60 using the
QIAamp Viral RNA Mini Kit (Qiagen), reverse-transcribed
as above, and serially diluted. RSV genomic RNA quantity in
each sample was calculated in “pfu equivalents.”Viral genome sequencing, phylogenetic analysis and real
time PCR
Viral RNA was extracted from clarified supernatants or
sucrose-purified virus using QIAampW Viral RNA Mini
kit (QIAGEN). Reverse transcriptase and PCR were per-
formed as previously described [12]. Primers used for
the sequencing of clinical isolates are listed in Additional
file 1. For sequence of the ends of the viral genome,
purified viral RNA was circularized by ligation using T4
RNA ligase (Epicentre, Madison, WI) as described else-
where [46]. Primers were designed (see Additional File 1)
to span the region of the ligated ends. The exact nucleo-
tide at the 3’ and 5’ ends were determined by comparison
to available genome sequences. DNA sequencing of PCR
products was performed by the McDermott Center Se-
quencing Core using Applied Biosystems Inc. (ABI) Big
Dye Terminator 3.1 chemistry and analyzed on ABI ca-
pillary instruments. Sequence analysis including align-
ment and integration of contigs, sequence comparisons
and alignments, and phylogenetic analysis were per-
formed using DNASTAR Lasegene 8 software (MegAlign
and Seqman).Additional file
Additional file 1: Primers Used for Sequencing of the genome of RSV
isolates.
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